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Materials and Methods 
Supplementary materials and sample handling 
Materials and reagents 
All reagents purchased from commercial sources were used as received unless otherwise stated. BBL trypticase 
soy agar (TSA) plates with 5% sheep blood and Bacto brain heart infusion (BHI) media were purchased from 
BD Biosciences. All antibiotic stock solutions and nucleic acid amplification reactions were prepared using 
sterile, nuclease-free water (NF-H2O) purchased from Thermo Fisher. Ciprofloxacin was purchased from 
Sigma-Aldrich and prepared as a 1 mg/mL stock solution in NF-H2O. Nitrofurantoin was purchased from 
Sigma-Aldrich and prepared as a 10 mg/mL stock solution in NF-H2O. QuickExtract DNA Extraction was 
purchased from Epicentre. QX200 ddPCR EvaGreen Supermix was purchased from Bio-Rad Laboratories. Bst 
3.0 and 10 mM dNTPs were purchased from NEB. Pooled healthy human urine was obtained from Lee 
Biosolutions. Primer sequences were ordered as dried stocks from IDT. 
Digital quantification with dPCR 
Droplet digital PCR reactions were carried out as described previously (26). 
Design, fabrication and preparation of SlipChips 
Details of the design, fabrication, preparation, and assembling of the single-volume 1,280-well SlipChip glass 
devices are described in previous work (50). For this manuscript, the workflow in Fig. 5 was performed with 
lab-made reusable glass microfluidic chips (Samples 28-29,48-51). To run the rest of the 54 samples with the 
rapid dLAMP assay, we obtained a set of disposable injection molded chips (5,376 2.4-nL compartments) from 
SlipChip Corp, which enabled shorter turnaround times between experiments (Samples 1-27,30-47). 
Clinical sample handling and gold-standard broth microdilution AST 
Urine from patients suspected of having urinary tract infections (UTIs) was collected and transported in a BD 
Vacutainer Urine Collection Tube containing formate and borate as preservatives. Next, pathogens from the 
urine samples were isolated and identified using mass spectrometry. Broth microdilution AST was performed 
on samples positive for E. coli. 
dAST with clinical samples 
One modification to our original dAST protocol (26) is the addition of DNase to digest extracellular DNA. We 
did this to eliminate the confounding effect that extracellular DNA could have on the CT ratio. Consider an 
antibiotic-susceptible sample with 500 cop/μL of cell-free DNA and 300 cop/μL DNA inside cells. If the 
genomes replicate 1.5X over a 15 min exposure time, then the CT ratio in the case where cell-free DNA is also 
detected would be 950 cop/uL ÷ 800 cop/uL = 1.19; in the case where cell-free DNA is digested by DNase and 
not detected, the CT ratio would be 450 cop/uL ÷ 300 cop/uL = 1.50. 
 
If discordant AST calls (compared to the gold-standard) were noticed on the same day, we re-ran that sample to 
resolve the discordancy. Some reruns are accepted even in the FDA submissions of diagnostic AST devices, so 
rerunning samples in itself is not a problem.  It would have been better to rerun the samples twice, to get a third 
measurement as a tie-breaker.  Unfortunately, we could not do so due to the limitations of our protocols and the 
concern for aging of clinical samples over time (and we were not able to rerun all of the samples).  
 
Because our data provide a quantitative measurement (CT ratio), we averaged the two runs to obtain a 
consensus value of the CT ratio. When we do this (using dPCR values as an example), we find that three 
samples (#28, #29, #43) returned average CT ratios (1.48, 1.07, 1.48) that were in agreement with the gold 
standard (S, R, S). For a fourth sample (#36), the average CT ratio (1.09) was also discordant with the gold 
standard (S) and we recorded it as an error in our analysis for both dPCR and dLAMP (see Table S1). 
 
Isolate maintenance and exposure experiments. 
For all experiments involving isolates (Fig. 2), isolates were maintained and antibiotic exposure carried out as 
described in previous work (26). All E. coli isolates were maintained on solid or liquid BHI media (BD), all 
Lactobacillus jensenii isolates were maintained on solid or liquid MRS media (BD). 
 
Intermediate samples 
In this manuscript, we focus on categorical agreement of our binary susceptibility determination (susceptible or 
resistant). We chose to design our study this way and to exclude intermediate samples for the following reasons:   
The current gold-standard antibiotic susceptibility testing method is broth dilution. This method, used every 
day in central clinical laboratories, is only accurate to +/- one dilution step. For example, E. coli with an 
initially determined ciprofloxacin MIC of 2.0 μg/mL might have an MIC of 1, 2, or 4 μg/mL if tested again 
using the same gold-standard method. According to the CLSI standards used in the US, 1.0 μg/mL is 
considered “susceptible”, while 2 μg/mL is considered “intermediate” and 4.0 μg/mL is considered resistant. 
This is well-known in the clinical microbiology community.  In fact, the CLSI manual (59) states that one of 
the roles of the intermediate category is to include a buffer zone which should prevent small, uncontrollable, 
technical factors from causing major discrepancies in interpretation. Furthermore, when gold standard broth 
dilution vs gold standard inhibition zone diameter is compared, intermediate samples do not show consistent 
results (see Fig. 4 of (60); of the five samples tested with intermediate MICs (as determined by the gold-
standard), the inhibition zone method called one of them resistant, two intermediate, and two susceptible 
(60)). 
A further issue is the discrepancy of the meaning “resistant and susceptible” around these concentrations.  
For example, using EUCAST standards, susceptible isolates are those with ciprofloxacin MIC of 0.25 
μg/mL and below, while intermediate isolates have MIC of 0.5 μg/mL and resistant isolates are 1.0 μg/mL 
and above. 
We chose to exclude samples with MICs of 0.5, 1.0, and 2.0 μg/mL to ensure that the gold standard method 
would not frequently switch between a susceptible and resistant call if repeated. 
Importantly, this approach is still applicable to “real world” samples and does not correspond to only 
looking at extremes of MIC.  Excluding these samples only eliminates a small percentage of E. coli samples 
based on epidemiological data [see “Ciproflaxin / Escherichia coli international MIC distribution” reference 
database (62)], with the caveat that these distributions may change at different times in different locations. 
For example: a broader range of antibiotic concentrations is tested when generating epidemiological data 
than is tested in clinical microbiology laboratories. The cut-off MIC for defining resistant and susceptible 
organisms is different between the epidemiological and clinical microbiological data.  Epidemiological cut 
off is defined relative to the wild-type susceptibility whereas the clinical cut off is defined relative to 
clinically relevant susceptibility.  These data should not be used to infer the rates of resistance in a particular 
geographical location at a particular time (62).  
For nitrofurantoin (nit), MIC of >=128 is considered resistant and MIC of <= 32 is considered susceptible. 
Similarly, we chose to exclude the minimal possible number of samples with MICs that might switch 
between a susceptible or resistant call when repeated. For this reason, we excluded samples with MICs of 32 
and 64 μg/mL. 
Therefore, it should not be surprising that when validating a new AST method with clinical samples, it is 
common to challenge the method only against susceptible and resistant samples that are above or below the 
MIC breakpoints, while avoiding intermediate samples (34, 35, 61). 
To test whether intermediate or near-intermediate samples provide any unexpected results, we did run a small 
separate study of 8 clinical isolates (2 operators with 4 isolates each) with intermediate and near-intermediate 
MICs using dPCR readout. We exposed these isolates with (1.0 μg/mL ciprofloxacin) and without antibiotics 
for 15 min and measured the nucleic acid concentrations with dPCR. Isolates with MIC of 1.0 μg/mL are 
clustering very close to the threshold and slightly below, while isolates with MIC of 0.5 μg/mL are comfortably 
above the threshold and would be read as susceptible (fig. S3). 
Theoretical analysis of phenotypic AST 
To explore the tradeoffs among antibiotic exposure time, the growth rate of the bacteria in question, and the 
required resolution of the measurement method, we developed a simple model to inform optimal AST methods 
when DNA replication is used as the differentiating marker between susceptible and resistant bacteria. We 
assumed that i) a sample containing bacteria with an initial concentration of a specific NA sequence, C0 
[mol/L], has a DNA doubling time of tdouble [min] when incubated in media for tinc [min], ii) an antibiotic-
susceptible bacteria sample incubated in media with antibiotics does not grow at all, and iii) antibiotic-resistant 
bacteria grow at the same rate with and without antibiotics. 
Under these assumptions, the ratio of the NA concentrations of a control sample (Ccontrol) compared to an 
antibiotic-treated sample (CABX)—the control–treated ratio (CT ratio)—after a certain time of antibiotic 
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Plotting CT ratio as a function of tinc and tdouble yields Fig. 1B. Typically, qPCR is capable of resolving 2-fold 
differences in concentration, whereas digital PCR (dPCR) can resolve as low as 1.2-fold differences in 
concentration (41). Due to the higher resolving power of dPCR, phenotypic AST can be performed with shorter 
antibiotic exposure times than if qPCR was used as the measurement method. 
 
Experimental details for LAMP primer design, optimization, and specificity. 
LAMP primer optimization experiments (Fig. 3A, steps 1–2) were performed on a Roche LightCyler 96 using 
the SYBR Green I channel for readout, 6 µL reaction volumes, and the following concentrations of reagents: 20 
mM Tris-HCl pH 8.8, 50 mM KCl, 10 mM (NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 µM Syto-9, 400 
U/mL Bst 2.0 (New England Biolabs), ~700 copies/µL E. coli gDNA, and 8 mM MgSO4. All samples were run 
across a temperature gradient spanning 60 – 72 ˚C. 
The experiments optimizing magnesium concentration (Fig. 3A, step 3) were performed using the same 
protocol as above with the following concentrations of reagents: 20 mM Tris-HCl pH 8.8, 150 mM KCl, 10 mM 
(NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 2 µM Syto-9, 360 U/mL Bst 3.0 (New England Biolabs), ~700 
copies/µL E. coli gDNA, and variable concentrations of MgSO4 (Fig. 3A). All samples were run across a 
temperature gradient spanning 60–74 ˚C. 
Primer concentrations were kept constant in all experiments: 1.6 µM FIP/BIP, 0.2 µM FOP/BOP, and 0.4 µM 
loopF/loopB (when included). The final selected primer set was as follows: GGCGTTAAGTTGCAGGGTAT 
(FOP), TCACGAGGCGCTACCTAA (BOP), 
CGGTTCGGTCCTCCAGTTAGTGTTTTCCCGAAACCCGGTGATCT (FIP), 
TAGCGGATGACTTGTGGCTGGTTTTTCGGGGAGAACCAGCTATC (BIP), ACCTTCAACCTGCCCATG 
(LoopF), GTGAAAGGCCAATCAAACC (LoopB). 
Identification and specificity experiments were performed using the same concentration of reagents as the 
experiments to optimize MgSO4 concentration, but were run with 5 mM MgSO4. Although 6 mM MgSO4 
yielded the fastest TTP, 5 mM MgSO4 was used in subsequent experiments in order to minimize the risk of 
background amplification. We have not observed background amplification with the primers described here, but 
other primer sets are sensitive to MgSO4 concentration. The optimal TTP using 5 mM MgSO4 was only 12 s 
slower than when using 6 mM MgSO4. 
BLAST was used to evaluate primer specificity against the families Enterobacteriaciae, Staphylococcaceae, 
and Enterococcaceae. The specificity of the LAMP primers targeting the E. coli 23S rDNA gene was tested 
against human genomic DNA (Hs gDNA), Lj gDNA, urine from healthy donors, and water (Fig. 3A,B). Hs 
gDNA was tested at 0.002, 0.02, and 0.2 ng/µL final reaction concentration as measured using a NanoDrop 
2000c (Thermo Fisher Scientific). Lj gDNA was tested at final reaction concentrations of 0.16, 0.8, and 1.6 
ng/µL, as measured using a NanoDrop 2000c. Urine from healthy donors was run at 10% final reaction volume. 
Real-time LAMP amplification was performed using a range of concentrations of E. coli gDNA (Ec gDNA) 
prepared from clinical UTI urine samples and quantified using droplet digital PCR (Fig. 3C). 
Rapid digital LAMP (dLAMP) 
Clinical urine samples were treated with and without 1 µg/mL cip or 16 µg/mL nit for 15 min and nucleic acids 
extracted as described above. The dLAMP mix consisted of 20 mM Tris-HCl pH 8.8, 150 mM KCl, 10 mM 
(NH4)2SO4, 0.1% Tween-20, 1.4 mM dNTPs, 1X EvaGreen (Biotium), 360 U/mL Bst 3.0, 1X RNase Cocktail 
(ThermoFisher), 5 mM MgSO4, and 1 mg/mL BSA prepared in NF-H2O. Aliquots of NA extractions composed 
10% or 20% of the final volume in the dLAMP mix. Two aliquots of dLAMP mix containing equal volumes of 
NA extractions from the control and treated samples were simultaneously loaded into two separate SlipChip 
devices. The top piece of each SlipChip was moved relative to the bottom piece, which partitioned the solution 
into 1,280 3-nL compartments (lab made glass SlipChips) or 5,376 2.4-nL compartments (injection-molded 
plastic SlipChips) (see Supplementary Materials). When using the injection-molded plastic SlipChips, the 
treated chip was loaded 30 s after the control chip. The SlipChips were then placed onto the thermal cycler of a 
digital real-time imaging instrument and incubated at 72 °C for 20 min (56). Amplification time was recorded 
starting from when the thermal cycler reached 72 °C. 
Images were taken every 20 s and the fluorescent intensity was measured for each compartment (Fig. 4A/F) 
with LabView software as described in (56). Wells that showed liquid movement or bubbles were excluded 
from analysis. If there was a spatial amplification gradient (i.e., positives in one area of the chip appeared before 
other areas), then the experiment was excluded. The concentration of the target was calculated using Poisson 
statistics and was based on the number of “positive” compartments that exceeded the fluorescence intensity 
threshold, for time points where 13 or more compartments were positive. The concentration of the control and 
treated samples was calculated in real-time, along with a P value representing the probability that the ratio of 
concentrations being greater than 1.10 was a result of random chance (Fig. 4C/H). If P < 0.05, we can be 
reasonably certain that the bacteria are susceptible to the antibiotic. If the P-value remains > 0.05, we can be 
reasonably certain that the bacteria are resistant to the antibiotic. The CT ratio was calculated and plotted for 
each 20 s interval in Fig. 4 D/I for one susceptible sample and one resistant sample. For Fig. 6C, the CT ratio at 
6.7 min was calculated and plotted for all 54 dAST experiments. 
In some cases, the TTP distribution (Fig. 4 B/G) of one chip was delayed relative to the other chip. If this 









Fig. S1. Resolution of digital devices. The resolution of digital quantification depends on the number and 
volume of compartments. Simulations were performed with the methods described in (45). A) For a fixed 
sample size, and fixed input concentration of 106 cop/mL relevant to UTIs, increasing the number of 
compartments (and reducing the volume of each compartment accordingly) beyond 1,000 does not improve 
resolution in a useful way. B) For fixed compartment volume, and fixed input concentration of 106 copy/mL 
relevant to UTIs, the resolution improves with increasing number of compartments, although this increase 
requires a larger input of sample and amplification reagents. C) Dependence of resolution on the number of 
multiplexed measurements made for a constant number of total wells.  For example, while 10,000 of 1 nL 
compartments provide 1.08 resolution, 2,000 of 1 nL compartments provide 1.16 resolution each, enabling a 4-





Fig. S2. Real-time dLAMP DNA quantification of a UTI sample with nit treatment. High-resolution single-
molecule nucleic acid amplification was performed using ultrafast digital LAMP (dLAMP) for digital 
antimicrobial susceptibility test (dAST) of clinical UTI urine samples with antibiotic-susceptible (A–E) and 
antibiotic-resistant (F–J) E. coli. Aliquots of a clinical UTI sample were treated with and without 16 μg/mL 
nitrofurantoin. After 15 min, DNA was extracted and quantified with digital LAMP on SlipChips. The protocols 
followed and materials used are described in Materials and Methods, “Digital AST (dAST) using clinical UTI 
samples” and Supplementary Materials Section 5. (A,F) Real-time fluorescence amplification traces (only 200 
of 1,280 traces shown for clarity). NFU = normalized fluorescence units; dotted line = positive threshold; when 
the normalized fluorescence intensity of a compartment crosses the threshold, that compartment is counted as 
positive. (B,G) Time-to-positive (TTP) distribution was determined by counting the number of compartments 
that crossed the positive threshold at each time point. (C,H) Detected concentrations of the target dAST marker 
in control and antibiotic-treated samples for successive image cycles. Grey lines represent 95% confidence 
intervals. Note these curves are not the amplification curves shown in A and F. (D,I) Detected control–treated 
(CT) ratios over time. Dashed line indicates susceptibility threshold. (E,J) Comparison of CT ratios for droplet 





Fig. S3. The dAST method tested with isolates with near-intermediate MICs. The digital AST (dAST) 
method was tested with clinical isolates from urinary tract infections(UTIs) using a 15 min treatment of 1 
μg/mL ciprofloxacin. Eight isolates with three near-intermediate MICs were analyzed with the dAST method 






Fig. S4. Reproducibility of the dAST method with clinical urine samples. Three ciprofloxacin-susceptible 
samples (#37, #38, #45 from table S1) were analyzed with the dAST method in triplicate and control–treated 




Table S1. Concentration of clinical urine samples. Pathogen-specific 23S DNA concentration as determined 
by digital LAMP after 6.7 min of amplification time (Fig. 4C/H). Taking into account the number of rDNA 
copies per E. coli chromosome, and the efficiency of dLAMP in counting DNA in 6.7 min, the concentration of 
full genomes is ~6 times lower than the number reported in this table. CFU/mL was determined by plate 











1 1.59E+07 >100,000  27 4.63E+07 >100,000 
2 2.52E+07 >100,000  28 3.62E+07 >100,000 
3 3.94E+07 >100,000  29 6.21E+06 >100,000 
4 5.63E+07 >100,000  30 2.38E+07 >100,000 
5 3.14E+07 >100,000  31 2.98E+07 >100,000 
6 7.86E+06 >100,000  32 9.57E+07 >100,000 
7 7.07E+06 >100,000  33 1.08E+08 >100,000 
8 5.08E+07 >100,000  34 1.13E+08 >100,000 
9 1.72E+07 >100,000  35 4.84E+07 >100,000 
10 2.64E+07 >100,000  36 5.73E+07 >100,000 
11 7.44E+06 >100,000  37 1.59E+07 >100,000 
12 2.75E+07 >100,000  38 8.49E+07 >100,000 
13 2.07E+07 >100,000  39 3.18E+06 50,000 
14 1.55E+07 >100,000  40 2.45E+07 >100,000 
15 2.12E+08 >100,000  41 1.02E+08 >100,000 
16 1.59E+07 >100,000  42 1.26E+07 >100,000 
17 5.12E+07 >100,000  43 4.97E+06 >100,000 
18 1.44E+07 >100,000  44 1.69E+08 >100,000 
19 2.62E+07 >100,000  45 2.46E+08 >100,000 
20 4.52E+06 >100,000  46 8.78E+06 >100,000 
21 4.25E+07 >100,000  47 8.58E+06 >100,000 
22 1.30E+08 >100,000  48 1.21E+07 >100,000 
23 3.04E+07 >100,000  49 1.41E+07 >100,000 
24 2.38E+07 >100,000  50 3.06E+06 >100,000 
25 4.19E+07 >100,000  51 8.02E+06 >100,000 
26 1.92E+07 >100,000     
 
  
Table S2. Clinical samples used in this study. Clinical urinary tract infection (UTI) urine samples tested for 
ciprofloxacin (cip) or nitrofurantoin (nit) susceptibility testing by gold-standard broth microdilution and by 
digital AST (dAST). Nucleic acids were quantified with both digital PCR (dPCR) and digital LAMP (dLAMP). 
Sample reruns (indicated by a “(2)”) were performed several hours later on the same day when the control-
treated ratio was discordant with the gold-standard AST call (CT ratio > 1.10 for a resistant sample or < 1.10 for 
a susceptible sample). S = antibiotic-susceptible; R = antibiotic-resistant; *major error; **very major error. 
Caltech 
Sample # 
UCLA ID # 
Description 


















1 15-31A-020 red, clear nit <16 S 1.48 S 1.64 S 
2 15-31A-022 light yellow, clear cip <=0.25 S 1.44 S 1.34 S 
3 15-31A-025 light yellow, clear nit <16 S 1.33 S 1.33 S 
4 15-31A-026 light yellow, clear nit <16 S 1.36 S 1.35 S 
5 15-31A-027 light yellow, clear nit <16 S 1.25 S 1.24 S 
6 15-31A-031 colorless, clear cip >=4 R 1.09 R 0.95 R 
6 15-31A-031 colorless, clear nit 256 R 0.95 R 0.77 R 
7 15-31A-039 light yellow, clear cip >=4 R 0.99 R 0.84 R 
8 15-31A-040 light yellow, clear nit 128 R 1.06 R 1.09 R 
9 15-31A-042 dark yellow, clear cip <=0.25 S 1.92 S 1.83 S 
10 15-31A-043 light yellow, clear cip <=0.25 S 1.66 S 1.85 S 
10 15-31A-043 light yellow, clear nit 128 R 0.91 R 0.92 R 
11 15-31A-049 light yellow, clear cip >=4 R 0.96 R 1.04 R 
12 15-31A-050 dark yellow, cloudy cip >=4 R 0.88 R 0.96 R 
13 15-31A-051 light yellow, cloudy cip >=4 R 0.98 R 0.97 R 
14 15-31A-054 light yellow, cloudy cip <=0.25 S 1.42 S 1.48 S 
15 15-31A-056 light yellow, cloudy nit 256 R 1.09 R 1.106 S** 
16 15-31A-060 light yellow, cloudy cip <=0.25 S 1.83 S 1.31 S 
17 15-31A-063 yellow, cloudy cip <=0.25 S 1.28 S 1.111 S 
18 15-31A-066 yellow, cloudy cip >=4 R 0.85 R 0.80 R 
19 15-31A-067 light yellow, cloudy cip >=4 R 0.82 R 0.59 R 
20 15-31A-068 light yellow, cloudy cip >=4 R 0.84 R 0.57 R 
21 15-31A-071 light yellow, cloudy cip >=4 R 1.04 R 0.92 R 
22 15-31A-079 light yellow, cloudy nit 128 R 1.25 S** 1.43 S** 
23 15-31A-084 yellow, clear cip >=4 R 1.01 R 0.96 R 
24 15-31A-086 yellow, cloudy cip <=0.25 S 2.01 S 2.21 S 
25 15-31A-088 yellow, cloudy cip <=0.25 S 1.25 S 1.22 S 
26 15-31A-089 light yellow, clear cip >=4 R 0.94 R 0.91 R 
27 15-31A-091 yellow, cloudy cip <=0.25 S 1.18 S 1.19 S 
28 15-31A-093 orange/red, clear cip <=0.25 S 1.08 R - - 
28(2) 15-31A-093 orange/red, clear cip <=0.25 S 1.88 S 1.59 S 
28_avg 15-31A-093 orange/red, clear cip <=0.25 S 1.48 S - - 
29 15-31A-096 light yellow, cloudy cip >=4 R 1.20 S - - 
29(2) 15-31A-096 light yellow, cloudy cip >=4 R 0.93 R 0.98 R 
29_avg 15-31A-096 light yellow, cloudy cip >=4 R 1.07 R - - 
30 15-31A-097 light yellow, cloudy cip >=4 R 1.13 S** 0.98 R 
31 15-31A-101 light yellow, clear nit <16 S 1.39 S 1.19 S 
32 15-31A-102 dark yellow, clear nit <16 S 1.63 S 1.68 S 
33 15-31A-103 light yellow, clear nit <16 S 1.38 S 1.28 S 
34 15-31A-105 light pink, cloudy nit <16 S 1.47 S 1.44 S 
35 15-31A-108 yellow,  cloudy nit <16 S 1.29 S 1.37 S 
36 15-31A-111 yellow, clear nit <16 S 1.02 R* - - 
36(2) 15-31A-111 yellow, clear nit <16 S 1.16 S 0.95 R* 
36_avg 15-31A-111 yellow, clear nit <16 S 1.09 R - - 
37 15-31A-112 yellow, clear nit <16 S 1.49 S 1.12 S 
38 15-31A-114 light yellow, clear nit <16 S 1.34 S 1.36 S 
39 15-31A-115 yellow, clear nit <16 S 1.44 S 1.48 S 
40 15-31A-116 dark yellow, cloudy cip >=4 R 1.05 R 0.75 R 
40 15-31A-116 dark yellow, cloudy nit <16 S 1.96 S 2.33 S 
41 15-31A-118 yellow, clear nit <16 S 1.25 S 1.15 S 
42 15-31A-119 light yellow, clear cip <=0.25 S 2.21 S 1.95 S 
43 15-31A-122 light yellow, clear nit <16 S 1.17 S - - 
43(2) 15-31A-122 light yellow, clear nit <16 S 1.79 S 1.45 S 
43_avg 15-31A-122 light yellow, clear nit <16 S 1.48 S - - 
44 15-31A-123 yellow, cloudy nit <16 S 1.18 S 1.15 S 
45 15-31A-126 light yellow, clear nit <16 S 1.24 S 1.19 S 
46 15-31A-131 light yellow, clear cip <=0.25 S 1.61 S 1.28 S 
47 15-31A-132 dark yellow, clear cip <=0.25 S 1.27 S 1.14 S 
48 15-31A-133 dark yellow, cloudy cip <=0.25 S 1.30 S 1.29 S 
49 15-31A-134 dark yellow, clear cip <=0.25 S 2.36 S 1.85 S 
50 15-31A-136 light yellow, clear cip <=0.25 S 2.04 S 1.89 S 
51 15-31A-137 dark yellow, clear cip <=0.25 S 1.43 S 1.28 S 
 
  
Table S3. Rapid phenotypic AST literature summary showing the state of the art. Phenotypic antibiotic 
susceptibility tests using clinical samples, blood culture, contrived samples, clinical isolates, or reference strains 
with reported total assay time less than 3.5 hrs (210 min). References are sorted by sample type then by 
combined time of all steps. NR = not reported. Literature from 1997–2017. 















Clinical Samples dAST (using dLAMP) 0 15 24 29 This work 
Clinical Samples ATP Bioluminescence 0 90 105 NR (61) 
Clinical Samples Microscopy 120 30 155 NR (28) 
Clinical Samples NA Quantification 0 120 204a NR (35) 
Clinical Samples Microscopy 0 206 206b NR (88) 
Clinical Samples Electrochemical 0 150 NR 210 (34) 
       
Contrived Samples Microfluidics 0 60 60 NR (89) 
Contrived Samples Electrochemical 0 60 100 NR (90) 
Contrived Samples Microfluidics 0 120 120 NR (91) 
       
Blood Culture Microscopy 0 40 45c NR (39) 
       
Clinical Isolates Microscopy 0 10 <30d NR (27) 
Clinical Isolates Microscopy 0 40 40 NR (39) 
Clinical Isolates Electrochemical 0 15 45 NR (33) 
Clinical Isolates FACS 0 90 95 NR (92) 
Clinical Isolates Magnetic Bead Rotation 90 15 120e NR (93) 
Clinical Isolates Microscopy 120 6 126 NR (28) 
Clinical Isolates Raman Spectroscopy 0 120 130f NR (94) 
Clinical Isolates Raman Spectroscopy 0 120 130f NR (95) 
Clinical Isolates dAST (using dPCR) 0 15 140 NR (26) 
Clinical Isolates FACS 0 120 150 NR (96) 
Clinical Isolates FACS 0 60 180 NR (97) 
Clinical Isolates Mass Spectrometry 0 60 180 NR (98) 
Clinical Isolates Microscopy 0 180 200g NR (29) 
Clinical Isolates Electrochemical 0 90 NR NR (34) 
       
Reference Strains Microscopy 0 3 <30d NR (27) 
Reference Strains Electrochemical 0 10 25 NR (32) 
Reference Strains Raman Spectroscopy 0 20 25f NR (95) 
Reference Strains Electrochemical 0 20 42 NR (99) 
Reference Strains Microfluidics 0 60 60 NR (100) 
Reference Strains FACS 0 120 120h NR (101) 
Reference Strains Raman Spectroscopy 0 120 130f NR (94) 
atime does not include washing and centrifugation steps 
bdetailed times of each step not reported, listed time is median time reported for all samples 
cdoes not include time of overnight blood culture growth 
dtotal time of all steps reported as “less than 30 min.” 
etime does not include washing steps 
fwashing, imaging, and agarose embedding time not included 
greported as “clinical samples” in the abstract, but methods clearly state that all work was performed with clinical isolates: “We tested 
189 clinical isolates…Before testing, each isolate was subcultured on cation-adjusted MHA for 20-24 hours” 
hdoes not include time of FACS measurement 
 
 
